High Quality 99% Erdafitinib ky1982,sag21k,way316606,way262611,infigratinib from Certified Professional Producer
TDS 168 Inquiries
2226664-93-1
Top Grade
99%
Shanghai,China
YH
1kg/drum,25kg/drum
Yes
2026-11-22
Food Additives,Active Pharm Ingredients,Chem & Pharm Intermediates,Organic Intermediates
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionCertificatesBasic Info
-
Product Name:
2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-
Other Name:2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-;2H-Indol-2-one, 5,6-dichloro-3-[1,3-dihydro-3-(methoxyimino)-2H-indol-2-ylidene]-1,3-dihydro-Ky19382;Glycogen synthase kinase 3,Beta catenin,β-catenin,GSK-3,KY 19382,inhibit,Wnt,Inhibitor,KY-19382,A 3051,KY19382,A-3051,Glycogen synthase kinase-3;5',6'-Dichloro-3-(methoxyimino)-[2,3'-biindolinylidene]-2'-one;KY19382(A3051);KY19382, 10 mM in DMSO;KY19382 (A3051) ,S6085;A3051
CAS No.:2226664-93-1
Molecular Formula:C17H11Cl2N3O2
InChIKeys:PROTUMHDKVZVBW-UHFFFAOYSA-N
Molecular Weight:360.19
Exact Mass:359.0228320
Color/Form:Brown to reddish brown
Categories:
Characteristics-
Density:
1.58±0.1 g/cm3(Predicted)
PKA:8.80±0.20(Predicted)
Research-
Class:
Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)
Status:Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)
Mechanism:Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.
EC50 (Fgfr1 Ic50):1.2 nM
EC50 (Fgfr3 Ic50):3.0 nM
EC50 (Fgfr2 Ic50):2.5 nM
EC50 (Fgfr4 Ic50):5.7 nM
EC50 (Vegfr2 Ic50):36.8 nM (approximately 30-fold selectivity vs FGFR1)
Source:Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI
Clinical Development:FDA:Balversa (approved 2019-04-12)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Approval announcement 2024-01-19; FDA: BALVERSA label (NDA 212018, BLC2001); NEJM: Loriot et al. (2023) — THOR Cohort 1; NEJM: Loriot et al. (2019) — BLC2001; Mol Cancer Ther: Perera et al. (2017) — discovery pharmacology
Disclaimer:Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Food Additives,Active Pharm Ingredients,Chem & Pharm Intermediates,Organic Intermediates
-
Location:
No.15 Qinling Avenue,Caotang Industrial Park,High-techZone,Xi'an Shaanxi China
-
Payment Terms:
L/C,100% TT in advance
-
Average lead Time:
15 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
51-100
-
Year of Establishment:
2024
-
-
Inquiry History168 Inquiries
Country Product Purchase Quantity Date Posted
Poland
Ky19382 CAS 2226664-93-1
1 G Oct 11, 2026
Australia
High Quality KY19382 99% powder 2226664-93-1 Shaanxi Dideu Medichem Co.Ltd
1 G Aug 15, 2026
Canada
Ky19382
1 G Oct 13, 2026
Australia
KY-19382
1 G Jul 18, 2026
Bulgaria
KY19383
100 G Oct 16, 2025
Algeria
KY19382
10 G Nov 30, 2025
Hungary
Ky19382
1 MT Oct 11, 2026
United States
KY19382
100 KG Nov 25, 2025
United States
KY19382
1 G Jul 21, 2026
Philippines
KY-19382 (CAS: 2226664-93-1)
450 G Aug 13, 2026
Russia
Ky19382
5 G Sep 19, 2026
Russia
Ky19382
10 G Sep 19, 2026
Russia
Ky-19382
5 G Sep 17, 2026
United States
Erdafitinib ky1982,sag21k,way316606,way262611,infigratinib
1 MT Oct 22, 2026
United States
KY-19382
1 G Oct 14, 2026
Canada
ky19382
0.25 G Oct 10, 2026
Australia
Ky19382
1 G Oct 8, 2026
United States
KY19382
1 G Oct 7, 2026
Israel
KY19382
1 G Oct 5, 2026
Israel
Ky19382
1 G Oct 5, 2026 Post an enquiry for this product
More from this Seller
-
-
-
dpg dipropylene glycol price cas 110-98-5 fragrance grade monomethyl ether acetate for perfume skin
Pharmaceutical Grade / 99%
-
-
-
-
High Quality 99% DAP 18-46 (Ammonium sulfate);CAS No.:7783-20-2 from YI HANG
Industrial Grade / 99%
-
-
-
-
China Hot selling high-quality products Fluorescein Dichloride; 76-54-0; 2, 7-Dichlorofluorescein
Pharmaceutical Grade / 99%
-
